menu
    • menu
    [{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"CYBIN","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Ketamine analogs","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Discovery Platform","graph3":"Adelia Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"Adelia Therapeutics \/ CYBIN","highestDevelopmentStatusID":"3","companyTruncated":"Adelia Therapeutics \/ CYBIN"},{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"CYBIN","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Fexofenadine Hydrochloride","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Adelia Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Adelia Therapeutics \/ CYBIN","highestDevelopmentStatusID":"12","companyTruncated":"Adelia Therapeutics \/ CYBIN"},{"orgOrder":0,"company":"Adelia Therapeutics","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Tryptamine derivatives","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Adelia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Adelia Therapeutics \/ Adelia","highestDevelopmentStatusID":"4","companyTruncated":"Adelia Therapeutics \/ Adelia"}]

    Find Clinical Drug Pipeline Developments & Deals by Adelia Therapeutics

    Menu

    Adelia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adelia Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Adelia Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tryptamine derivatives

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : Cybin

                            Deal Size : $0.8 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Purs...

                            Details : The achievement includes the successful synthesis of multiple tryptamine derivatives in sufficient quantities, drug ADME/PK has been completed and to demonstrate “In Vitro” ADME “Proof of Principle” that specific synthesis modifies the metabolism...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 11, 2021

                            Lead Product(s) : Tryptamine derivatives

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : Cybin

                            Deal Size : $0.8 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adelia Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Adelia Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fexofenadine Hydrochloride

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : CYBIN

                            Deal Size : $15.75 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent F...

                            Details : Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. -Adelia leadership bring extensive clinical and commercialization experience of major drugs, including Allegra, Sabril,...

                            Brand Name : Allegra

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 14, 2020

                            Lead Product(s) : Fexofenadine Hydrochloride

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : CYBIN

                            Deal Size : $15.75 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Adelia Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Adelia Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine analogs

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery Platform

                            Sponsor : CYBIN

                            Deal Size : $15.7 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cybin Signs Definitive Agreement To Acquire Adelia Therapeutics As Part Of Its Commitment To Strategic Growth

                            Details : Adelia’s leadership team brings deep clinical and commercialization experience, including past commercial success in psychedelics through the development of proprietary ketamine analogs as well as strong understanding of the underlying science.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 07, 2020

                            Lead Product(s) : Ketamine analogs

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery Platform

                            Sponsor : CYBIN

                            Deal Size : $15.7 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth